The Cellular and Molecular Immunotherapy in Prostate Cancer

Overview

Journal Vaccines (Basel)

Date 2022 Aug 26

PMID 36016257

Authors

Anirban Goutam Mukherjee

Uddesh Ramesh Wanjari

D S Prabakaran

Raja Ganesan

Kaviyarasi Renu

Abhijit Dey

Balachandar Vellingiri

Sabariswaran Kandasamy

Thiyagarajan Ramesh

Abilash Valsala Gopalakrishnan

Affiliations

Soon will be listed here.

Abstract

In recent history, immunotherapy has become a viable cancer therapeutic option. However, over many years, its tenets have changed, and it now comprises a range of cancer-focused immunotherapies. Clinical trials are currently looking into monotherapies or combinations of medicines that include immune checkpoint inhibitors (ICI), CART cells, DNA vaccines targeting viruses, and adoptive cellular therapy. According to ongoing studies, the discipline should progress by incorporating patient-tailored immunotherapy, immune checkpoint blockers, other immunotherapeutic medications, hormone therapy, radiotherapy, and chemotherapy. Despite significantly increasing morbidity, immunotherapy can intensify the therapeutic effect and enhance immune responses. The findings for the immunotherapy treatment of advanced prostate cancer (PCa) are compiled in this study, showing that is possible to investigate the current state of immunotherapy, covering new findings, PCa treatment techniques, and research perspectives in the field's unceasing evolution.

Citing Articles

Comprehensive analysis of macrophage-related genes in prostate cancer by integrated analysis of single-cell and bulk RNA sequencing.

Zhang J, Li Z, Chen Z, Shi W, Xu Y, Huang Z Aging (Albany NY). 2024; 16(8):6809-6838.

PMID: 38663915 PMC: 11087116. DOI: 10.18632/aging.205727.

Knowledge mapping and current trends of m6A methylation in the field of cancer.

Zhu C, Yang J, Zhang C, Wang Y, Wang J Heliyon. 2024; 10(4):e26262.

PMID: 38434062 PMC: 10906179. DOI: 10.1016/j.heliyon.2024.e26262.

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer.

Wang Q, Feng C, Chen Y, Peng T, Li Y, Wu K J Immunol Res. 2023; 2023:2473075.

PMID: 37719086 PMC: 10505079. DOI: 10.1155/2023/2473075.

Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer.

Ye F, Dewanjee S, Li Y, Jha N, Chen Z, Kumar A Mol Cancer. 2023; 22(1):105.

PMID: 37415164 PMC: 10324146. DOI: 10.1186/s12943-023-01805-y.

CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy.

Zhang H, Liu D, Qin Z, Yi B, Zhu L, Xu S Front Oncol. 2023; 13:1170397.

PMID: 37388224 PMC: 10301743. DOI: 10.3389/fonc.2023.1170397.

References

Al-Maghrabi J, Bakshi N, Farsi H . Gleason grading of prostate cancer in needle core biopsies: a comparison of general and urologic pathologists. Ann Saudi Med. 2013; 33(1):40-4. PMC: 6078572. DOI: 10.5144/0256-4947.2013.40. View

Zahm C, Moseman J, Delmastro L, McNeel D . PD-1 and LAG-3 blockade improve anti-tumor vaccine efficacy. Oncoimmunology. 2021; 10(1):1912892. PMC: 8078506. DOI: 10.1080/2162402X.2021.1912892. View

Alemohammad H, Najafzadeh B, Asadzadeh Z, Baghbanzadeh A, Ghorbaninezhad F, Najafzadeh A . The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. Biomed Pharmacother. 2021; 146:112516. DOI: 10.1016/j.biopha.2021.112516. View

D S P, Chaturvedi P, Shimokawa T, Kim K, Park W . Silencing of Fused Toes Homolog (FTS) Increases Radiosensitivity to Carbon-Ion Through Downregulation of Notch Signaling in Cervical Cancer Cells. Front Oncol. 2021; 11:730607. PMC: 8576531. DOI: 10.3389/fonc.2021.730607. View

Jeong S, Kwak C . Immunotherapy for prostate cancer: Requirements for a successful regime transfer. Investig Clin Urol. 2022; 63(1):3-13. PMC: 8756154. DOI: 10.4111/icu.20210369. View

Schmidt-Hegemann N, Fendler W, Ilhan H, Herlemann A, Buchner A, Stief C . Outcome after PSMA PET/CT based radiotherapy in patients with biochemical persistence or recurrence after radical prostatectomy. Radiat Oncol. 2018; 13(1):37. PMC: 5833127. DOI: 10.1186/s13014-018-0983-4. View

Li X, Xiang Y, Li F, Yin C, Li B, Ke X . WNT/β-Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. Front Immunol. 2019; 10:2293. PMC: 6775198. DOI: 10.3389/fimmu.2019.02293. View

Bayati F, Mohammadi M, Valadi M, Jamshidi S, Foma A, Sharif-Paghaleh E . The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities. Front Immunol. 2021; 11:585819. PMC: 7844143. DOI: 10.3389/fimmu.2020.585819. View

Jafari S, Molavi O, Kahroba H, Hejazi M, Maleki-Dizaji N, Barghi S . Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol Life Sci. 2020; 77(19):3693-3710. PMC: 11104895. DOI: 10.1007/s00018-020-03459-1. View

10.

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

11.

Ness N, Andersen S, Rakaee Khanehkenari M, Nordbakken C, Valkov A, Paulsen E . The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget. 2017; 8(16):26789-26801. PMC: 5432297. DOI: 10.18632/oncotarget.15817. View

12.

Dudzinski S, Cameron B, Wang J, Rathmell J, Giorgio T, Kirschner A . Combination immunotherapy and radiotherapy causes an abscopal treatment response in a mouse model of castration resistant prostate cancer. J Immunother Cancer. 2019; 7(1):218. PMC: 6694548. DOI: 10.1186/s40425-019-0704-z. View

13.

Youlin K, Li Z, Xiaodong W, Xiuheng L, Hengchen Z . Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer. Clin Dev Immunol. 2012; 2012:439235. PMC: 3270651. DOI: 10.1155/2012/439235. View

14.

Al-Hashimi M . Trends in Breast Cancer Incidence in Iraq During the Period 2000-2019. Asian Pac J Cancer Prev. 2021; 22(12):3889-3896. PMC: 9080353. DOI: 10.31557/APJCP.2021.22.12.3889. View

15.

Muthusami S, Prabakaran D, Yu J, Park W . EGF-induced expression of Fused Toes Homolog (FTS) facilitates epithelial-mesenchymal transition and promotes cell migration in ME180 cervical cancer cells. Cancer Lett. 2014; 351(2):252-9. DOI: 10.1016/j.canlet.2014.06.007. View

16.

Fay E, Graff J . Immunotherapy in Prostate Cancer. Cancers (Basel). 2020; 12(7). PMC: 7409298. DOI: 10.3390/cancers12071752. View

17.

Tian J, Liu Y, Zhang T, Yue L, Xiao Y, Guo C . LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy. Expert Rev Anticancer Ther. 2022; 22(3):289-296. DOI: 10.1080/14737140.2022.2039124. View

18.

Cai T, Santi R, Tamanini I, Galli I, Perletti G, Bjerklund Johansen T . Current Knowledge of the Potential Links between Inflammation and Prostate Cancer. Int J Mol Sci. 2019; 20(15). PMC: 6696519. DOI: 10.3390/ijms20153833. View

19.

Disis M . Mechanism of action of immunotherapy. Semin Oncol. 2014; 41 Suppl 5:S3-13. DOI: 10.1053/j.seminoncol.2014.09.004. View

20.

Prabakaran D, Muthusami S, Sivaraman T, Yu J, Park W . Silencing of FTS increases radiosensitivity by blocking radiation-induced Notch1 activation and spheroid formation in cervical cancer cells. Int J Biol Macromol. 2018; 126:1318-1325. DOI: 10.1016/j.ijbiomac.2018.09.114. View